BRAF and neoplasm: According to major guidelines and experts’ recommendations, therapeutic choice could be guided by a combination of clinical considerations (i.e., patient’s age and performance status, comorbidities, expectations and preferences, primary tumor location, treatment toxicity profile, physician’s experience) and tumor molecular characteristics (i.e., RAS and BRAF mutational status) [1].